A share price of Phathom Pharmaceuticals Inc [PHAT] is currently trading at $10.62, down -3.89%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PHAT shares have gain 15.94% over the last week, with a monthly amount drifted -1.48%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, March 2024, Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”. In a post published today on Yahoo Finance, National TV and digital media campaign aims to motivate millions of people suffering from Erosive GERD to learn more about VOQUEZNA® (vonoprazan), the first and only FDA-approved potassium-competitive acid blocker (PCAB).
From an analyst’s perspective:
Phathom Pharmaceuticals Inc [NASDAQ: PHAT] stock has seen the most recent analyst activity on January 05, 2024, when Needham reiterated its Buy rating and also boosted its price target to $26 from $23. Previously, H.C. Wainwright started tracking the stock with Buy rating on August 09, 2023, and set its price target to $28. On May 11, 2023, upgrade upgraded it’s rating to Outperform. Craig Hallum started tracking the stock assigning a Buy rating and suggested a price target of $21 on March 13, 2023. Jefferies initiated its recommendation with a Buy and recommended $16 as its price target on October 21, 2022. Evercore ISI downgraded its rating to In-line for this stock on May 06, 2022. In a note dated May 12, 2021, Goldman upgraded an Neutral rating on this stock and boosted its target price from $40 to $48.
Phathom Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $6.07 and $17.02. Currently, Wall Street analysts expect the stock to reach $30.33 within the next 12 months. Phathom Pharmaceuticals Inc [NASDAQ: PHAT] shares were valued at $10.62 at the most recent close of the market. An investor can expect a potential return of 185.59% based on the average PHAT price forecast.
Analyzing the PHAT fundamentals
Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at -245.33%, Pretax Profit Margin comes in at -295.59%, and Net Profit Margin reading is -295.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is 4.94 and Total Capital is -0.45. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.91.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.29 points at the first support level, and at 9.95 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.09, and for the 2nd resistance point, it is at 11.55.
Phathom Pharmaceuticals Inc [PHAT] reported earnings per share of -$1.39 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.08/share, meaning a difference of -$0.31 and a surprise factor of -28.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.76 per share as compared to estimates of -$0.89 per share, a difference of $0.13 representing a surprise of 14.60%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Phathom Pharmaceuticals Inc [NASDAQ:PHAT] is 10.25. In addition, the Quick Ratio stands at 10.22 and the Cash Ratio stands at 9.83. Considering the valuation of this stock, the price to sales ratio is 913.32.
Transactions by insiders
Recent insider trading involved Curran Terrie, President and Chief Executive, that happened on Mar 22 ’24 when 16851.0 shares were sold. 10% Owner, TAKEDA PHARMACEUTICAL CO LTD completed a deal on Jan 24 ’24 to sell 3.7 million shares. Meanwhile, CFO and CBO Henderson Molly sold 6307.0 shares on Jan 19 ’24.
